<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191228045917N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-04-17</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Effect of pulse duration on laser-assisted hair removal</public_title>
      <acronym></acronym>
      <scientific_title>Effect of different pulse durations on the efficacy of long-pulsed Alexandrite-assisted hair removal,A split-face comparison study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-06-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/44585</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: ّFor random allocation of treatment with two different settings ( pulse duration : 3 versus 10 msec), at first, face of subject is divided to 2 parts (right and left),then we generate 50 (number of our subjects) random samples with block randomization with considering 2 treatments and 4,6 and 8 blocks .Finally , we consider one side of face (that is chosen randomly) constant and based on random sequence generated, allocate the treatment with 10 msec pulse duration to that side of face.It is obvious that the other side will undergo treatment with 3 msec pulse duration.  
For generation of random sequence , we will use an online software with this address : 
 https://www.sealedenvelope.com/simple-randomiser/v1/lists, Blinding description: our subjects will not know each side of their faces will be treated with which pulse duration.
two dermatologists that evaluate the photographs are also blinded about the allocation of pulse durations.
data analysis also will be done blindly.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Hirsutism.</hc_freetext>
      <i_freetext>Intervention 1: intervention group: using the manufacture-recommended methods and settings, one side of the face of each patient (randomly determinded) is treated with a 10 msec pulse duration  using an alexandrite laser ( Gentlase Pro. ,Candela, USA).treatment is conducted every 5 weeks for 3 sessions.hair counts and photographs are obtained before treatment and 1 month postoperatively.This laser has a wavelength of 755 nm , a wide range of pulse duration (3 -300 msec) , ability to generate fluence up to 150 J/cm2 and different spotsizes (6 to 18 mm). Intervention 2: control group: using the manufacture-recommended methods and settings, the other side of the face of each patient  is treated with a 3 msec pulse duration  using an alexandrite laser ( Gentlase Pro. ,Candela, USA).treatment is conducted every 5 weeks for 3 sessions.hair counts and photographs are obtained before treatment and 1 month postoperatively.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
all patient information can be shared without naming and identifying them

When:
details of the data are immediately available after publishing the results

To whom:
all researchers and health professionals working in academic,scientific and medical institutions

Conditions:
the data is only shared for person whose purpose is to improve the therapeutic course of hirsutism.Any type of statistical analysis can be done in order to improve the treatment

Where to obtain:
Tehran university of medical sciences professor Pedram Nourmohamad Pour Dermatologist Razi hospital, Wahdat-e-eslami  Ave., Tehran, District 12 Phone number +98 9128240659  e mail : normohamad@razi.tums.ac.ir

How to obtain:
information is available immediately after verifying that the applicant,s circumstances are met by the competent authorities

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zeynab Aryanian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Razi hospital,Wahdat-e-eslami Ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1199663911</zip>
        <telephone>+98 21 5561 8989</telephone>
        <email>z_aryanian@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Pedram Nourmohamad pour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Razi hospital,Wahdat-e-eslami Ave.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1199663911</zip>
        <telephone>+98 21 5561 8989</telephone>
        <email>normohamad@razi.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>age 18 and above
facial hirsutism with clinical diagnosis by a dermatologist</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>in the last 3 months has not recieved any drug for hirsutism
severe photosensitivity
keloidal or hypertrophic scar tendency
recent sun exposure
pregnancy or lactation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L68.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Hirsutism</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>intervention group: using the manufacture-recommended methods and settings, one side of the face of each patient (randomly determinded) is treated with a 10 msec pulse duration  using an alexandrite laser ( Gentlase Pro. ,Candela, USA).treatment is conducted every 5 weeks for 3 sessions.hair counts and photographs are obtained before treatment and 1 month postoperatively.This laser has a wavelength of 755 nm , a wide range of pulse duration (3 -300 msec) , ability to generate fluence up to 150 J/cm2 and different spotsizes (6 to 18 mm).</i_keyword>
      <i_keyword>control group: using the manufacture-recommended methods and settings, the other side of the face of each patient  is treated with a 3 msec pulse duration  using an alexandrite laser ( Gentlase Pro. ,Candela, USA).treatment is conducted every 5 weeks for 3 sessions.hair counts and photographs are obtained before treatment and 1 month postoperatively.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The percentage of hair regrowth. Timepoint: at sessions 5,10,15 weeks , the percentage of hair regrowth is measured. Method of measurement: by photographic evaluation by 2 other dermatologists.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-01-12</approval_date>
        <contact_name>Ethics committee of Tehran university of medical sciences</contact_name>
        <contact_address>No. 1,Poorsina Ave.,Ghods Ave.,Enghelab Ave. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
